Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal

With ambitious sales goals and its stock trading at an all-time high, cancer diagnostics firm Exact Sciences decided to go shopping. The result is a deal announced Monday to acquire Genomic Health in a $2.8 billion cash-and-stock deal that Exact CEO Kevin Conroy argues will create a global leader in the sector.